RS60417B9 - Amorfni oblik aktivnog jedinjenja koje inhibira pirimidinil-ciklopentansko jedinjenje, smeše i njegove metode - Google Patents

Amorfni oblik aktivnog jedinjenja koje inhibira pirimidinil-ciklopentansko jedinjenje, smeše i njegove metode

Info

Publication number
RS60417B9
RS60417B9 RS20200729A RSP20200729A RS60417B9 RS 60417 B9 RS60417 B9 RS 60417B9 RS 20200729 A RS20200729 A RS 20200729A RS P20200729 A RSP20200729 A RS P20200729A RS 60417 B9 RS60417 B9 RS 60417B9
Authority
RS
Serbia
Prior art keywords
compositions
methods
amorphous form
cyclopentane compound
akt inhibiting
Prior art date
Application number
RS20200729A
Other languages
English (en)
Inventor
Paroma Chakravarty
Sanjeev Kothari
Francis Gosselin
Scott J Savage
Jeffrey Stults
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48539412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60417(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of RS60417B1 publication Critical patent/RS60417B1/sr
Publication of RS60417B9 publication Critical patent/RS60417B9/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
RS20200729A 2012-05-17 2013-05-17 Amorfni oblik aktivnog jedinjenja koje inhibira pirimidinil-ciklopentansko jedinjenje, smeše i njegove metode RS60417B9 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648536P 2012-05-17 2012-05-17
PCT/US2013/041728 WO2013173811A1 (en) 2012-05-17 2013-05-17 Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof
EP13726362.0A EP2858989B9 (en) 2012-05-17 2013-05-17 Amorphous form of an akt inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof

Publications (2)

Publication Number Publication Date
RS60417B1 RS60417B1 (sr) 2020-07-31
RS60417B9 true RS60417B9 (sr) 2021-07-30

Family

ID=48539412

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200729A RS60417B9 (sr) 2012-05-17 2013-05-17 Amorfni oblik aktivnog jedinjenja koje inhibira pirimidinil-ciklopentansko jedinjenje, smeše i njegove metode

Country Status (31)

Country Link
US (2) US9290458B2 (sr)
EP (2) EP2858989B9 (sr)
JP (2) JP6283663B2 (sr)
KR (4) KR20210095238A (sr)
CN (1) CN104470912B (sr)
AU (2) AU2013262548B2 (sr)
BR (1) BR112014028593A2 (sr)
CA (1) CA2873663C (sr)
CL (1) CL2014003115A1 (sr)
CO (1) CO7151489A2 (sr)
CR (1) CR20140560A (sr)
DK (1) DK2858989T3 (sr)
ES (1) ES2799512T3 (sr)
HK (1) HK1208462A1 (sr)
HR (1) HRP20200992T1 (sr)
HU (1) HUE051254T2 (sr)
IL (2) IL235712B (sr)
LT (1) LT2858989T (sr)
MA (1) MA37650A1 (sr)
MX (1) MX353041B (sr)
MY (1) MY170086A (sr)
NZ (1) NZ702513A (sr)
PE (1) PE20150725A1 (sr)
PH (1) PH12014502538B1 (sr)
PL (1) PL2858989T3 (sr)
PT (1) PT2858989T (sr)
RS (1) RS60417B9 (sr)
RU (1) RU2650511C2 (sr)
SG (1) SG11201407618VA (sr)
SI (1) SI2858989T1 (sr)
WO (1) WO2013173811A1 (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702513A (en) 2012-05-17 2016-09-30 Genentech Inc Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof
NZ702935A (en) 2012-05-17 2017-02-24 Genentech Inc Process for making hydroxylated cyclopentylpyrimidine compounds
EP4282973A3 (en) 2013-11-15 2024-03-27 F. Hoffmann-La Roche AG Processes for the preparation of pyrimidinylcyclopentane compounds
DK2946774T3 (da) 2014-05-19 2020-05-25 Tillotts Pharma Ag Coatede kapsler med modificeret frigivelse
TW202329972A (zh) * 2016-08-10 2023-08-01 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
JP2022544485A (ja) * 2019-08-12 2022-10-19 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Atp競合性akt阻害剤、cdk4/6阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
EP4351522A1 (en) * 2021-06-09 2024-04-17 Lonza Bend Inc. Mixed solvents for spray drying for preparation of amorphous solid dispersions
WO2023043869A1 (en) 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408197A (pt) 1993-12-12 1997-08-26 Agrogene Ltd Método para proteger plantas contra doenças fúngicas
WO1998044797A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
AU3386600A (en) 1999-03-03 2000-09-21 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
MXPA04007433A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
WO2004108673A2 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
KR101223914B1 (ko) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Akt 단백질 키나제 억제제
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CA2711699A1 (en) * 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
MX2011010905A (es) 2009-04-15 2011-11-01 Abbott Lab Compuestos antivirales.
EA020151B1 (ru) 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
MX2012011887A (es) * 2010-04-16 2012-11-30 Genentech Inc Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt.
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
NZ702935A (en) 2012-05-17 2017-02-24 Genentech Inc Process for making hydroxylated cyclopentylpyrimidine compounds
MX350443B (es) 2012-05-17 2017-09-06 Genentech Inc Proceso para hacer compuestos de aminoácidos.
CA2873661C (en) 2012-05-17 2020-07-21 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
WO2013173736A1 (en) 2012-05-17 2013-11-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
NZ702513A (en) 2012-05-17 2016-09-30 Genentech Inc Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
CA2904662A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
PL2858989T3 (pl) 2020-11-16
IL235712A0 (en) 2015-02-01
RU2650511C2 (ru) 2018-04-16
BR112014028593A2 (pt) 2017-12-19
MX2014013856A (es) 2015-02-18
EP3719014A1 (en) 2020-10-07
MX353041B (es) 2017-12-18
PH12014502538A1 (en) 2015-01-21
HUE051254T2 (hu) 2021-03-01
PT2858989T (pt) 2020-06-25
RS60417B1 (sr) 2020-07-31
AU2013262548A1 (en) 2015-01-15
DK2858989T3 (da) 2020-06-02
KR20200074252A (ko) 2020-06-24
AU2017279607B2 (en) 2018-11-22
IL272037A (en) 2020-02-27
PH12014502538B1 (en) 2015-01-21
CN104470912B (zh) 2017-11-14
ES2799512T3 (es) 2020-12-18
MY170086A (en) 2019-07-04
US9290458B2 (en) 2016-03-22
CL2014003115A1 (es) 2015-07-03
CA2873663C (en) 2020-01-14
KR20210095238A (ko) 2021-07-30
JP2018062536A (ja) 2018-04-19
WO2013173811A1 (en) 2013-11-21
KR20150020200A (ko) 2015-02-25
AU2017279607C1 (en) 2019-05-16
SI2858989T1 (sl) 2020-08-31
HRP20200992T1 (hr) 2020-10-16
AU2013262548B2 (en) 2017-09-21
JP6283663B2 (ja) 2018-02-21
SG11201407618VA (en) 2015-01-29
MA37650A1 (fr) 2016-11-30
JP2015517533A (ja) 2015-06-22
IL272037B (en) 2020-10-29
CN104470912A (zh) 2015-03-25
EP2858989A1 (en) 2015-04-15
JP6518352B2 (ja) 2019-05-22
RU2014151016A (ru) 2016-07-10
US20160152575A1 (en) 2016-06-02
US9505725B2 (en) 2016-11-29
NZ702513A (en) 2016-09-30
PE20150725A1 (es) 2015-05-17
US20150274677A1 (en) 2015-10-01
CR20140560A (es) 2015-01-12
EP2858989B9 (en) 2021-04-14
KR102125588B1 (ko) 2020-06-22
CA2873663A1 (en) 2013-11-21
IL235712B (en) 2020-01-30
AU2017279607A1 (en) 2018-01-18
EP2858989B1 (en) 2020-05-06
HK1208462A1 (en) 2016-03-04
LT2858989T (lt) 2020-08-10
KR20220143143A (ko) 2022-10-24
CO7151489A2 (es) 2014-12-29

Similar Documents

Publication Publication Date Title
IL272037B (en) An amorphous form of a pyrimidinyl-cyclopentane compound inhibits akt, its preparations and methods
IL235944A0 (en) β-lactamase inhibitor compounds, preparations containing them, methods for their preparation and their uses
IL238958A0 (en) Glutamase inhibitors, preparations containing them and their uses
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
IL238959A (en) Glutamase suppressors, preparations containing them and their uses
LT2920149T (lt) 3-aminocikloalkilo junginiai, kaip ror-gama-t inhibitoriai, ir jų panaudojimas
EP2834322A4 (en) BIOCHARBON COMPOSITIONS AND METHODS OF USE
EP2763665A4 (en) ANTIMICROBIAL COMPOSITIONS AND METHODS USING SAME
EP2848967A4 (en) FILM-COMPOSITE COMPOSITION
EP2582664A4 (en) PHENYL THIOACETATE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
AP3597A (en) Imidazopyridazines as akt kinase inhibitors
EP2858648A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING PIN1
HK1207824A1 (en) Polymorph compositions, methods of making, and uses thereof
HK1198365A1 (en) Imidazopyridine compounds, compositions and methods of use
EP2906041A4 (en) COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND
EP2931280A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1
EP2536431A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING MMSET
IL235312A0 (en) Taxane compounds, preparations and methods
AU2012901658A0 (en) Compositions and methods of use